Zacks Investment Research·Jun 23, 2026
New Strong Sell Stocks for June 23rdARR, AMTB and AMPH have been added to the Zacks Rank #5 (Strong Sell) List on June 23rd, 2026.
Amphastar Pharmaceuticals, Inc.(AMPH)Earnings, Financials & Key Ratios
AMPH•NASDAQ
$20.08
9.9× P/E·Price updated Jul 7, 2026
AboutAmphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Show more
- Revenue$720M-1.7%
- EBITDA$149M-43.2%
- Net Income$98M-38.5%
- EPS (Diluted)2.03-33.7%
- Gross Margin49.46%-3.2%
- EBITDA Margin20.71%-42.3%
- Operating Margin19.5%-30.5%
- Net Margin13.63%-37.5%
- ROE12.9%-44.5%
AMPH Price & Volume
Amphastar Pharmaceuticals, Inc. (AMPH) stock price & volume — 10-year historical chart
Loading chart...
Margin Compression Challenges Amidst Stagnant Revenue Growth
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Decelerating
Profitability:Strained
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Margin compression and R&D
Key Thesis Takeaways
- Amphastar faces a challenging transition as revenue growth has decelerated to a marginal 0.4% in 2026Q1, signaling difficulty in maintaining momentum within the competitive specialty pharmaceutical market.
- While the company maintains a disciplined debt-to-equity ratio of 0.89, structural margin erosion and high stock-based compensation expenses—which reached $9.3 million in 2026Q1—continue to weigh on net profitability.
- Investors should monitor whether ongoing investments in property, plant, and equipment, which grew to $378.9 million, can eventually restore operating margins from their current 8.0% level.
Verdict Logic
while the stock trades at a forward P/E of 8.12, the significant decoupling of cash flow from net income and the erosion of operating margins to 8.0% warrant a cautious wait-and-see approach.
AMPH Growth Metrics
Amphastar Pharmaceuticals, Inc. (AMPH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years11.09%
5 Years15.53%
3 Years12.99%
TTM-1.06%
Profit CAGR
10 Years-
5 Years133.84%
3 Years2.39%
TTM-44.06%
EPS CAGR
10 Years-
5 Years134.54%
3 Years5.27%
TTM-39.86%
Return on Capital
10 Years8.02%
5 Years15.19%
3 Years15.13%
Last Year9.77%
AMPH Recent Earnings
Amphastar Pharmaceuticals, Inc. (AMPH) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.42-40.0%
$0.70
Rev
$171M-1.3%
$173M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.73-19.2%
$0.90
Rev
$183M-3.0%
$189M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.93+20.8%
$0.77
Rev
$192M+0.7%
$190M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.85+19.7%
$0.71
Rev
$174M-1.5%
$177M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.42vs $0.70-40.0% | $171Mvs $173M-1.3% |
| Q1 2026 | Feb 26, 2026 | $0.73vs $0.90-19.2% | $183Mvs $189M-3.0% |
| Q4 2025 | Nov 6, 2025 | $0.93vs $0.77+20.8% | $192Mvs $190M+0.7% |
| Q3 2025 | Aug 7, 2025 | $0.85vs $0.71+19.7% | $174Mvs $177M-1.5% |
Based on last 12 quarters of dataView full earnings history →
Latest AMPH News
Recent stock market news and headlines for Amphastar Pharmaceuticals, Inc. (AMPH)
Peers Comparison
Key metrics vs top competitors for Amphastar Pharmaceuticals, Inc. (AMPH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $20.08 | $885.39M | 9.89 | -1.65% | 13.63% | 12.9% | — | |
| $103.41 | $6.73B | 30.33 | 0.5% | 18.05% | 24.33% | — | |
| $25.82 | $1.02B | 161.38 | 3.63% | 1.27% | 1.31% | — | |
| $11.19 | $1.55B | -1.09 | -2.75% | -43.5% | -50.65% | — | |
| $54.65 | $4.5B | -14.57 | — | — | -30.58% | — | |
| $47.41 | $2.73B | -69.72 | 8.63% | -3.74% | -2.73% | — |
Compare AMPH vs Peers
Amphastar Pharmaceuticals, Inc. (AMPH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AMPH SEC Filings & Documents
Amphastar Pharmaceuticals, Inc. (AMPH) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 16, 2026·SEC
Material company update
Mar 6, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when AMPH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AMPH Frequently Asked Questions
Amphastar Pharmaceuticals, Inc. (AMPH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Amphastar Pharmaceuticals, Inc.'s revenue?
Amphastar Pharmaceuticals, Inc. (AMPH) reported $720.5M in revenue for fiscal year 2025. This represents a 253% increase from $204.3M in 2012.
How fast is Amphastar Pharmaceuticals, Inc. growing?
Amphastar Pharmaceuticals, Inc. (AMPH) saw revenue decline by 1.7% over the past year.
Is AMPH profitable?
Yes, Amphastar Pharmaceuticals, Inc. (AMPH) is profitable, generating $79.2M in net income for fiscal year 2025 (13.6% net margin).
Dividend & Returns
What is AMPH's return on equity?
Amphastar Pharmaceuticals, Inc. (AMPH) has a return on equity (ROE) of 12.9%. This is reasonable for most industries.
What is Amphastar Pharmaceuticals, Inc.'s free cash flow?
Amphastar Pharmaceuticals, Inc. (AMPH) generated $135.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.